Bulumtatug fuvedotin clinical trials
How each study uses bulumtatug fuvedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bulumtatug fuvedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
16 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 4
Mabwell (Shanghai) Bioscience Co., Ltd. (11) · Convalife (Shanghai) Co., Ltd. (1) · Peking University Third Hospital (1) · Fudan University (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
Often tested with
Tested in the same studies.
Toripalimab (3) · CVL006 (1) · Trastuzumab rezetecan (1) · Tizetatug rezetecan (1) · Ruzaltatug rezetecan (1) · Notiretatug rezetecan (1) · Famitinib (1) · Disitamab vedotin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test bulumtatug fuvedotin, phase 3 first.
- Sep 20279MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerPhase 3 · Mabwell (Shanghai) Bioscience Co., Ltd.
- Dec 20269MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerPhase 1/2 · Mabwell (Shanghai) Bioscience Co., Ltd.
- May 2027A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCsPhase 1 · Mabwell (Shanghai) Bioscience Co., Ltd.
Studies
Open first, then newest update. How each study uses bulumtatug fuvedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCsRecruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT06908928Written as bulumtatug fuvedotin
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as 9MW2821
- Clinical Study of CVL006 Combination With 9MW2821Not yet recruitingPhase 1/2Convalife (Shanghai) Co., Ltd.NCT07615660Written as CVL006 in combination with 9MW2821
- A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerNot yet recruitingPhase 3Mabwell (Shanghai) Bioscience Co., Ltd.NCT07556848Written as 9MW2821
- JS207 Combination Therapy in Triple-negative Breast CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07045311Written as JS207 in combination with 9MW2821
- NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUCNot yet recruitingPhase 2Peking University Third HospitalNCT07412171Written as 9MW2821
- 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial CancerRecruitingPhase 2Mabwell (Shanghai) Bioscience Co., Ltd.NCT07314723Written as 9MW2821
- A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06947226Written as 9MW2821
- A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerRecruitingPhase 3Mabwell (Shanghai) Bioscience Co., Ltd.NCT06196736Written as 9MW2821
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerRecruitingPhase 2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06492005Written as 9MW2821
- A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerRecruitingPhase 3Mabwell (Shanghai) Bioscience Co., Ltd.NCT06692166Written as 9MW2821
- 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerRecruitingPhase 1/2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06079112Written as 9MW2821
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerRecruitingPhase 3Mabwell (Shanghai) Bioscience Co., Ltd.NCT06592326Written as 9MW2821
- A Clinical Study of 9MW2821 in Advanced Malignant Solid TumorsRecruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT05773937Written as 9MW2821
- Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)RecruitingPhase 1The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06551233Written as 9MW2821
- A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid TumorsRecruitingPhase 1/2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05216965Written as 9MW2821
Given beside what is tested · 2 — bulumtatug fuvedotin is usual care or a partner of the new treatment
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as 9MW2821
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaRecruitingPhase 2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06823427Written as 9MW2821
Codes
What other systems call bulumtatug fuvedotin · ClinicalTrials.gg INT014693
- UNII (FDA) 3L9KU8WUU3BULUMTATUG FUVEDOTINOne source FDA
- NCI Thesaurus C200283Bulumtatug FuvedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3L9KU8WUU3 | BULUMTATUG FUVEDOTIN | One source FDA |
| NCI Thesaurus | C200283 | Bulumtatug Fuvedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.